Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.82
PRXL's Cash to Debt is ranked higher than
55% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. PRXL: 0.82 )
PRXL' s 10-Year Cash to Debt Range
Min: 0.17   Max: No Debt
Current: 0.82

Equity to Asset 0.33
PRXL's Equity to Asset is ranked higher than
53% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PRXL: 0.33 )
PRXL' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.72
Current: 0.33

0.3
0.72
Interest Coverage 12.30
PRXL's Interest Coverage is ranked higher than
52% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRXL: 12.30 )
PRXL' s 10-Year Interest Coverage Range
Min: 3.16   Max: 118
Current: 12.3

3.16
118
F-Score: 8
Z-Score: 3.40
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 6.82
PRXL's Operating margin (%) is ranked higher than
84% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. PRXL: 6.82 )
PRXL' s 10-Year Operating margin (%) Range
Min: -1.77   Max: 8.44
Current: 6.82

-1.77
8.44
Net-margin (%) 4.81
PRXL's Net-margin (%) is ranked higher than
84% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. PRXL: 4.81 )
PRXL' s 10-Year Net-margin (%) Range
Min: -18.09   Max: 6.28
Current: 4.81

-18.09
6.28
ROE (%) 17.81
PRXL's ROE (%) is ranked higher than
94% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. PRXL: 17.81 )
PRXL' s 10-Year ROE (%) Range
Min: -68.39   Max: 17.81
Current: 17.81

-68.39
17.81
ROA (%) 5.39
PRXL's ROA (%) is ranked higher than
89% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. PRXL: 5.39 )
PRXL' s 10-Year ROA (%) Range
Min: -24.48   Max: 6.82
Current: 5.39

-24.48
6.82
ROC (Joel Greenblatt) (%) 36.43
PRXL's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. PRXL: 36.43 )
PRXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.68   Max: 38.44
Current: 36.43

-6.68
38.44
Revenue Growth (%) 13.90
PRXL's Revenue Growth (%) is ranked higher than
86% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. PRXL: 13.90 )
PRXL' s 10-Year Revenue Growth (%) Range
Min: 1   Max: 23.9
Current: 13.9

1
23.9
EBITDA Growth (%) 15.80
PRXL's EBITDA Growth (%) is ranked higher than
91% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. PRXL: 15.80 )
PRXL' s 10-Year EBITDA Growth (%) Range
Min: -10.9   Max: 56.3
Current: 15.8

-10.9
56.3
EPS Growth (%) 31.40
PRXL's EPS Growth (%) is ranked higher than
95% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. PRXL: 31.40 )
PRXL' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 36.4
Current: 31.4

-26.8
36.4
» PRXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PRXL Guru Trades in Q1 2013

Ken Fisher 2,650,339 sh (+3.61%)
Vanguard Health Care Fund 2,590,400 sh (unchged)
Chuck Royce 601,600 sh (unchged)
Joel Greenblatt 115,560 sh (-25.52%)
Paul Tudor Jones 10,100 sh (-37.65%)
Jim Simons 103,700 sh (-52.64%)
Steven Cohen 17,263 sh (-57.79%)
» More
Q2 2013

PRXL Guru Trades in Q2 2013

Jim Simons 137,500 sh (+32.59%)
Steven Cohen 19,768 sh (+14.51%)
Vanguard Health Care Fund 2,936,400 sh (+13.36%)
Ken Fisher 2,649,794 sh (-0.02%)
Joel Greenblatt 108,668 sh (-5.96%)
Chuck Royce 554,700 sh (-7.8%)
Paul Tudor Jones 9,100 sh (-9.9%)
» More
Q3 2013

PRXL Guru Trades in Q3 2013

Jim Simons 418,900 sh (+204.65%)
Paul Tudor Jones 9,200 sh (+1.1%)
Vanguard Health Care Fund 2,936,400 sh (unchged)
Ken Fisher 2,629,274 sh (-0.77%)
Chuck Royce 475,000 sh (-14.37%)
Steven Cohen 11,260 sh (-43.04%)
Joel Greenblatt 46,486 sh (-57.22%)
» More
Q4 2013

PRXL Guru Trades in Q4 2013

Steven Cohen 241,514 sh (+2044.88%)
Paul Tudor Jones 18,351 sh (+99.47%)
Vanguard Health Care Fund 4,805,700 sh (+63.66%)
Jim Simons 636,100 sh (+51.85%)
Ken Fisher 2,587,749 sh (-1.58%)
Chuck Royce 455,000 sh (-4.21%)
Joel Greenblatt 22,428 sh (-51.75%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-12-31 Add 63.66%0.26%$38.93 - $54.85 $ 49.268%4805700
Joel Greenblatt 2013-12-31 Reduce -51.75%0.04%$38.93 - $54.85 $ 49.268%22428
Joel Greenblatt 2013-09-30 Reduce -57.22%0.12%$46.43 - $51.33 $ 49.261%46486
Joel Greenblatt 2013-03-31 Reduce -25.52%0.07%$29.59 - $39.54 $ 49.2641%115560
Joel Greenblatt 2012-09-30 Add 64.33%0.11%$26.98 - $31.09 $ 49.2672%139526
Joel Greenblatt 2012-06-30 Add 37.93%0.05%$25 - $28.38 $ 49.2686%84905
Joel Greenblatt 2012-03-31 Add 165.31%0.09%$20.46 - $28.22 $ 49.26117%61558
Joel Greenblatt 2011-12-31 New Buy0.06%$18.26 - $22.63 $ 49.26144%23202
George Soros 2011-03-31 Sold Out $19.96 - $25.06 $ 49.26119%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.60
PRXL's P/E(ttm) is ranked higher than
73% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. PRXL: 25.60 )
PRXL' s 10-Year P/E(ttm) Range
Min: 6.48   Max: 52.08
Current: 25.6

6.48
52.08
P/B 4.60
PRXL's P/B is ranked higher than
61% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PRXL: 4.60 )
PRXL' s 10-Year P/B Range
Min: 0.98   Max: 5.32
Current: 4.6

0.98
5.32
P/S 1.30
PRXL's P/S is ranked higher than
96% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. PRXL: 1.30 )
PRXL' s 10-Year P/S Range
Min: 0.33   Max: 1.77
Current: 1.3

0.33
1.77
PFCF 25.50
PRXL's PFCF is ranked higher than
66% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. PRXL: 25.50 )
PRXL' s 10-Year PFCF Range
Min: 9.43   Max: 99999999.99
Current: 25.5

9.43
99999999.99
EV-to-EBIT 18.50
PRXL's EV-to-EBIT is ranked higher than
60% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. PRXL: 18.50 )
PRXL' s 10-Year EV-to-EBIT Range
Min: 7.1   Max: 237.1
Current: 18.5

7.1
237.1
PEG 2.60
PRXL's PEG is ranked higher than
54% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. PRXL: 2.60 )
PRXL' s 10-Year PEG Range
Min: 0.22   Max: 30.93
Current: 2.6

0.22
30.93
Shiller P/E 44.30
PRXL's Shiller P/E is ranked higher than
59% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. PRXL: 44.30 )
PRXL' s 10-Year Shiller P/E Range
Min: 19   Max: 428.17
Current: 44.3

19
428.17

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.00
PRXL's Price/Tangible Book is ranked lower than
73% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PRXL: 14.00 )
PRXL' s 10-Year Price/Tangible Book Range
Min: 1.13   Max: 33.72
Current: 14

1.13
33.72
Price/DCF (Projected) 2.10
PRXL's Price/DCF (Projected) is ranked higher than
79% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. PRXL: 2.10 )
PRXL' s 10-Year Price/DCF (Projected) Range
Min: 1.44   Max: 8.33
Current: 2.1

1.44
8.33
Price/Median PS Value 1.40
PRXL's Price/Median PS Value is ranked higher than
54% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PRXL: 1.40 )
PRXL' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 4.57
Current: 1.4

0.4
4.57
Price/Peter Lynch Fair Value 2.40
PRXL's Price/Peter Lynch Fair Value is ranked higher than
62% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. PRXL: 2.40 )
PRXL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.39   Max: 12.15
Current: 2.4

0.39
12.15
Price/Graham Number 3.90
PRXL's Price/Graham Number is ranked lower than
52% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. PRXL: 3.90 )
PRXL' s 10-Year Price/Graham Number Range
Min: 0.88   Max: 6.05
Current: 3.9

0.88
6.05
Earnings Yield (Greenblatt) 5.40
PRXL's Earnings Yield (Greenblatt) is ranked higher than
66% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PRXL: 5.40 )
PRXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 14.2
Current: 5.4

0.4
14.2
Forward Rate of Return (Yacktman) 11.97
PRXL's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. PRXL: 11.97 )
PRXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 35.6
Current: 11.97

-0.5
35.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PAX.Germany
Parexel International Corporation was incorporated in 1983. The Company provides a range of expertise in clinical research, medical communications, consulting, commercialization and informatics and advanced technology services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company has three reporting segments: Clinical Research Services ('CRS'), PAREXEL Consulting and Medical Communications Services ('PCMS'), and Perceptive Informatics ('Perceptive'). CRS constitutes its core business and includes all phases of clinical research from 'first-in-man' trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice ('GMP') compliance consulting. In addition, PCMS provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PCMS consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. Additionally, PCMS provides reimbursement and market access ('RMA') services. Perceptive provides information technology solutions designed to improve clients' product development processes. Perceptive's portfolio of products and services includes ClinPhone RTSM, medical imaging services, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. It competes with other biopharmaceutical services companies and other clinical research organizations ('CROs') that provide one or more of the services currently being offered by it. Some of the biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., inVentiv Health, INC Research, and Icon plc, offer services that compete directly with its services at many levels.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide